Mr. Mariani brings over 25 years of experience as a valued partner and strategic financial leader across several high growth medical technology companies. Prior to joining CytoSorbents, Mr. Mariani served as Executive Vice President and CFO of Axogen, Inc., a medical technology company focused on peripheral nerve repair and regeneration, from March 2021 to December 2023, and as its CFO from March 2016 the March 2021.
At Axogen, Mr. Mariani was responsible for all finance and accounting functions, investor relations, information technology and security, and Global Quality. During his tenure, Axogen grew annual revenue from $27 million to nearly $160 million, expanded from one to four nerve repair clinical applications, raised approximately $250 million of capital, executed a comprehensive clinical evidence development and publication strategy, and completed a long-term facility build-out. Prior to Axogen, Mr. Mariani was the Chief Financial Officer of Lensar, Inc., which at the time was privately held and a global leader in next generation femtosecond laser technology for refractive cataract surgery.
Prior to Lensar, he served as Chief Financial Officer at Hansen Medical, Inc., a publicly traded company that designed and manufactured medical robotics for positioning and control of catheter-based technologies. Mr. Mariani’s career also includes 12 years with Guidant Corporation, a global leader in the development and sale of medical devices for the treatment of cardiovascular disease. During his tenure at Guidant, he held senior financial positions of increasing importance, including Vice President of Finance and Administration, Guidant Japan, and Corporate Vice President, Controller and Chief Accounting Officer. He started his career at Ernst and Young, LLP, where he served a diverse client base as a Certified Public Accountant. Mr. Mariani earned a Bachelor of Science in accounting from Indiana University.
What is Peter J. Mariani's net worth?
The estimated net worth of Peter J. Mariani is at least $82.58 thousand as of December 13th, 2024. Mr. Mariani owns 20,068 shares of Cytosorbents stock worth more than $82,580 as of October 6th. This net worth approximation does not reflect any other assets that Mr. Mariani may own. Learn More about Peter J. Mariani's net worth.
How do I contact Peter J. Mariani?
Has Peter J. Mariani been buying or selling shares of Cytosorbents?
Peter J. Mariani has not been actively trading shares of Cytosorbents during the past quarter. Most recently, on Friday, December 13th, Peter J. Mariani bought 1,000 shares of Cytosorbents stock. The stock was acquired at an average cost of $19.20 per share, with a total value of $19,200.00. Following the completion of the transaction, the chief financial officer now directly owns 20,068 shares of the company's stock, valued at $385,305.60. Learn More on Peter J. Mariani's trading history.
Who are Cytosorbents' active insiders?
Are insiders buying or selling shares of Cytosorbents?
During the last twelve months, Cytosorbents insiders bought shares 4 times. They purchased a total of 216,846 shares worth more than $197,529.60. The most recent insider tranaction occured on September, 15th when CEO
Phillip P. Chan bought 3,774 shares worth more than $22,644.00. Insiders at Cytosorbents own 7.8% of the company.
Learn More about insider trades at Cytosorbents. Information on this page was last updated on 9/15/2026.
